ARENTFOX SCHIFF LLP for ORGANOGENESIS INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Medical device excise tax generally H.R. 195 (Making further continuing appropriations for the fiscal year ending September 30, 2018, and for other purposes), Section 4001 regarding extension of medical device excise tax
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILIP ENGLISH | — |
| DAN RENBERG | — |
Health Issues HCR
Food and Drug Administration policy on chronic wound healing products Food and Drug Administration user fee policy Federal research funding for wound healing products
| Lobbyist | Covered position, as disclosed |
|---|---|
| JAMES RAVITZ | — |
| DAN RENBERG | — |
Medicare/Medicaid MMM
Medicare reimbursement policy for chronic wound healing products H.R. 1625 (Consolidated Appropriations Act, 2018), Section 1301, regarding Medicare reimbursement policy for wound healing products
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAN RENBERG | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.